دوشنبه هجدهم آذر ۱۳۹۲ - ۶:۳۰ ب.ظ - دکتر لیلا (مهستی) جویباری -
Lu Zhou, Peninsula School of Medicine and Dentistry, UK
"KSR1 as a Potential Therapeutic Target for Both NF1 and NF2"
NF1 patients can develop plexiform neurofibromas (benign tumors that grow along nerves) which can become malignant peripheral nerve sheath tumors (MPNST) in 10% of cases. NF2 patients are likely to develop tumors of the Schwann cells called schwannomas, which lead to significant medical problems. Currently, there is no approved drug therapy for these complications of NF1 and NF2. This project will use cell cultures to explore the tumor-suppressing activity of Kinase Suppressor of Ras 1 (KSR1) as a new approach for the treatment of both NF1 and NF2
http://www.ctf.org/item/2013-young-investigator-award-recipients-announced.html
http://www.ctf.org/item/2013-young-investigator-award-recipients-announced.html
Shuning He, Harvard University, Dana-Farber Cancer Institute"In Vivo Analysis of the NF1 Tumor Suppressor in Neurofibromatosis"It is known that part of the NF1 protein down-regulates the function of another protein, called RAS, which can promote tumor formation when it is expressed at high levels. However, the functions of other regions of the NF1 protein have yet to be discovered. This project will study new functions of NF1 and how NF1 is involved in neurofibromatosis formation using a zebrafish model. When the functions of NF1 proteins are inhibited in zebrafish, they develop abnormally with defects that mirror the human disorder. The zebrafish model promises to be meaningful for the study of NF1 in humans and the development of improved therapies for patients with NF1
دانشجویان می توانند به لینک داده شده بروند و مطالب را ترجمه کنند. اگر ترجمه ها درست و روان باشد برای کار کلاسی زبان تخصصی امتیاز آن لحاظ می شود و معادل کار کلاسی محسوب می گردد.
بسم الله الرحمن الرحیم